[
  {
    "ts": null,
    "headline": "Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)",
    "summary": "Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)",
    "url": "https://finnhub.io/api/news?id=5396dc50bae2cf88fb2cad0e40ff1bb7979c1a7a66573670cb244f4dcfa85011",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743321600,
      "headline": "Earn A Potentially 12%-15% Income: Monthly Options Series (April 2025)",
      "id": 133610520,
      "image": "",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5396dc50bae2cf88fb2cad0e40ff1bb7979c1a7a66573670cb244f4dcfa85011"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
    "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
    "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743310800,
      "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
      "id": 133598030,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453972690/image_1453972690.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
      "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Life Sciences Investors Q4 2024 Commentary",
    "summary": "The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=66dc9f2b53ce613484d516524a22eafdccbe115cabd59877c7d52f9cd1ad811b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743306600,
      "headline": "abrdn Life Sciences Investors Q4 2024 Commentary",
      "id": 133594341,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205513/image_1322205513.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=66dc9f2b53ce613484d516524a22eafdccbe115cabd59877c7d52f9cd1ad811b"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Healthcare Investors Q4 2024 Commentary",
    "summary": "The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=82f91dbf63848ebe808f64808c8e5edf8521e08d31f59b25f79fc61ada48f984",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743303000,
      "headline": "abrdn Healthcare Investors Q4 2024 Commentary",
      "id": 133590926,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91598774/image_91598774.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=82f91dbf63848ebe808f64808c8e5edf8521e08d31f59b25f79fc61ada48f984"
    }
  }
]